Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks .

What is Kiniksa Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12 month target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 71.8% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts .

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 on January 1st, 2024. Since then, KNSA stock has decreased by 0.5% and is now trading at $17.46. View the best growth stocks for 2024 here .

Are investors shorting Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average daily trading volume, of 375,600 shares, the short-interest ratio is presently 8.5 days. View Kiniksa Pharmaceuticals' Short Interest .

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our KNSA earnings forecast .

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.15. The business had revenue of $83.40 million for the quarter, compared to analyst estimates of $72.31 million. Kiniksa Pharmaceuticals had a negative trailing twelve-month return on equity of 6.12% and a net margin of 5.11%.

What ETF holds Kiniksa Pharmaceuticals' stock?

Virtus LifeSci Biotech Products ETF holds 20,851 shares of KNSA stock, representing 2.10% of its portfolio.

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com . Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL) , CRISPR Therapeutics (CRSP) , Pfizer (PFE) , VBI Vaccines (VBIV) , SCYNEXIS (SCYX) , Sorrento Therapeutics (SRNE) , AbbVie (ABBV) , Dicerna Pharmaceuticals (DRNA) , Vaxart (VXRT) and Advanced Micro Devices (AMD) .

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends .

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:KNSA

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free KNSA Stock Alerts

$17.46

+0.02 (+0.11%)

(As of 04:32 PM ET)

Compare

Today's Range: $17.33
▼
$17.61
50-Day Range: $17.29
▼
$21.74
52-Week Range: $10.65
▼
$22.09

Volume: 304,729 shs
Average Volume: 400,905 shs
Market Capitalization: $1.23 billion

P/E Ratio: 97.01
Dividend Yield: N/A
Price Target: $30.00

Get Kiniksa Pharmaceuticals alerts:

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 71.8% Upside
$30.00 Price Target
Short Interest: Bearish
4.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 3 Articles This Week
Insider Trading: Selling Shares
$709,929 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.06) to ($0.44) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.14 out of 5 stars

Medical Sector

346th out of 930 stocks

Pharmaceutical Preparations Industry

152nd out of 420 stocks

3.5

Analyst's Opinion

Consensus Rating
Kiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Kiniksa Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.55% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Kiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 8.5.
Change versus previous month
Short interest in Kiniksa Pharmaceuticals has recently increased by 11.85%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Kiniksa Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Kiniksa Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KNSA.

3.2

News and Social Media Coverage

News Sentiment
Kiniksa Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
3 people have searched for KNSA on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,929.00 in company stock.
Percentage Held by Insiders
54.23% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Kiniksa Pharmaceuticals are expected to decrease in the coming year, from ($0.06) to ($0.44) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kiniksa Pharmaceuticals is 97.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.71.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kiniksa Pharmaceuticals is 97.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 217.84.
Price to Book Value per Share Ratio
Kiniksa Pharmaceuticals has a P/B Ratio of 2.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KNSA Stock News Headlines

March 16, 2024 | insidertrades.com

Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CEO Sells 5,582 Shares of Stock

April 16, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

April 16, 2024 | americanbankingnews.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Short Interest Up 11.8% in March

April 6, 2024 | americanbankingnews.com

Research Analysts Set Expectations for Kiniksa Pharmaceuticals, Ltd.'s FY2024 Earnings (NASDAQ:KNSA)

April 2, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart

March 7, 2024 | msn.com

5 Biotech Stocks With 26% Upside Potential or More

March 3, 2024 | investing.com

Earnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST sales

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 3, 2024 | wsj.com

Kiniksa Pharmaceuticals Ltd.

March 1, 2024 | seekingalpha.com

Kiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Full Year 2023 Earnings: Beats Expectations

March 1, 2024 | finance.yahoo.com

Chief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)

February 29, 2024 | finance.yahoo.com

Are You Looking for a Top Momentum Pick? Why Kiniksa Pharmaceuticals, Ltd. (KNSA) is a Great Choice

February 29, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Call Transcript

February 28, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: G1 Therapeutics (GTHX), Kiniksa Pharmaceuticals (KNSA)

February 28, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals Ltd (KNSA) Reports Strong Revenue Growth in Q4 and Full-Year 2023

February 28, 2024 | globenewswire.com

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution

February 28, 2024 | markets.businessinsider.com

What Wall Street expects from Kiniksa Pharmaceuticals's earnings

February 21, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 21, 2024 | globenewswire.com

Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

February 12, 2024 | msn.com

Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

February 12, 2024 | finance.yahoo.com

Kiniksa Pharmaceuticals, Ltd. (KNSA) is on the Move, Here's Why the Trend Could be Sustainable

February 12, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 38.07% Upside in Kiniksa Pharmaceuticals, Ltd. (KNSA): Here's What You Should Know

January 31, 2024 | uk.finance.yahoo.com

GSK (GSK) Misses Q4 Earnings Estimates

January 23, 2024 | finance.yahoo.com

How Much Upside is Left in Kiniksa Pharmaceuticals, Ltd. (KNSA)? Wall Street Analysts Think 43.93%

January 15, 2024 | finance.yahoo.com

Investors in Kiniksa Pharmaceuticals (NASDAQ:KNSA) have seen returns of 30% over the past year

See More Headlines

Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:KNSA
CUSIP: N/A
CIK: 1730430
Web: www.kiniksa.com
Phone: (781) 431-9100
Fax: N/A
Employees: 297
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.00
High Stock Price Target: $30.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +71.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.18
Trailing P/E Ratio: 97.23
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $14.08 million
Net Margins: 5.11%
Pretax Margin: -6.16%
Return on Equity: -6.12%
Return on Assets: -5.20%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.34
Quick Ratio: 3.85

Sales & Book Value

Annual Sales: $270.26 million
Price / Sales: 4.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.23 per share
Price / Book: 2.81

Miscellaneous

Outstanding Shares: 70,610,000
Free Float: 32,320,000
Market Cap: $1.24 billion
Optionable: Optionable
Beta: 0.27

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Mr. Sanj K. Patel (Age 55)
CEO & Chairman of the Board
Comp: $1.44M
Mr. Eben Tessari (Age 42)
Senior VP & COO
Comp: $643.75k
Dr. John F. Paolini (Age 59)
Senior VP & Chief Medical Officer
Comp: $753.7k
Mr. Mark Ragosa C.F.A. (Age 50)
Senior VP & CFO
Mr. Michael R. Megna CPA (Age 53)
Chief Accounting Officer & Group VP of Finance
Ms. Mei Jang
Senior VP of Technical Operations
Rachel Frank
Associate Director of Investor Relations
Mr. Chad Morin
Senior VP & Chief Compliance Officer
Ms. Madelyn Demsky Zeylikman (Age 50)
SVP, General Counsel & Secretary
Ms. Melissa Manno
Senior VP & Chief Human Resources Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings or view top-rated stocks.
What is Kiniksa Pharmaceuticals' stock price target for 2024?: 1 equities research analysts have issued 12 month target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 71.8% from the stock's current price.
View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts.
How have KNSA shares performed in 2024?: Kiniksa Pharmaceuticals' stock was trading at $17.54 on January 1st, 2024. Since then, KNSA stock has decreased by 0.5% and is now trading at $17.46.
View the best growth stocks for 2024 here.
Are investors shorting Kiniksa Pharmaceuticals?: Kiniksa Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average daily trading volume, of 375,600 shares, the short-interest ratio is presently 8.5 days.
View Kiniksa Pharmaceuticals' Short Interest.
When is Kiniksa Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our KNSA earnings forecast.
How were Kiniksa Pharmaceuticals' earnings last quarter?: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.15. The business had revenue of $83.40 million for the quarter, compared to analyst estimates of $72.31 million. Kiniksa Pharmaceuticals had a negative trailing twelve-month return on equity of 6.12% and a net margin of 5.11%.

What ETF holds Kiniksa Pharmaceuticals' stock?: Virtus LifeSci Biotech Products ETF holds 20,851 shares of KNSA stock, representing 2.10% of its portfolio.
What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?: 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Kiniksa Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).
When did Kiniksa Pharmaceuticals IPO?: Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Who are Kiniksa Pharmaceuticals' major shareholders?: Kiniksa Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.20%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel.
View institutional ownership trends.
How do I buy shares of Kiniksa Pharmaceuticals?: Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial